The Board of the Stichting Katholieke Universiteit has appointed Dr. Bertine Lahuis as Chair of the Executive Board of the Radboud university medical center from 1 January 2020. She succeeds Prof. Paul Smits, whose term of office will expire at that time.
Bertine Lahuis has been a member of the Executive Board of Radboud university medical center since December 2017, with the focus areas of patient care, quality of care, and patient safety.
Loek Hermans, Chair of the Board of the Stichting Katholieke Universiteit: “Over the past two years, Bertine Lahuis has shown herself to be a strong leader who has won great recognition, both inside as well as outside Radboud university medical center. Her appointment guarantees the continuation of the chosen course of Radboud university medical center.”
Bertine Lahuis says the following about her appointment: “It is an honor that Radboud university medical center puts their trust in me to fulfill the role of Chair. In the past two years, I have experienced the organization as being innovative, person-centered, and driven. The healthcare landscape will be very dynamic in the coming years; Radboud university medical center will make a significant contribution to society with its combination of care, education, and research. I look forward to - together with all employees - enabling Radboud university medical center to play a leading role in all networks in which we operate: regional, national, and international.”
Bertine Lahuis (1967) is a child psychiatrist and previously was the Chair of the Executive Board of Karakter, the expertise center for child and youth psychiatry in Gelderland and Overijssel. In 2016 she was elected Zorgmanager van het Jaar (care manager of the year). Bertine Lahuis studied Medicine at Utrecht University, where she also completed the Psychiatry program and she received her PhD in 2008.
Paul Smits took on the role of Chair of the Executive Board during the illness and after the death of Leon van Halder in March 2019. The board of the Stichting Katholieke Universiteit is very grateful for his commitment.
From 1 January 2020, the Executive Board will consist of Dr. Bertine Lahuis (Chair), Professor Jan Smit (Dean/Vice Chair), and Cees Buren MBA RC (CFO). Recruitment to fill the vacancy created by the appointment of Bertine Lahuis will be started as soon as possible. The procedure for the succession of Cees Buren from 1 April 2020 is ongoing.
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
Does the COVID-19 cytokine storm exist? Research may have an impact on the chances of success of a specific treatment4 September 2020
Following the measurement of several important cytokines in patients with COVID-19 and various other severe diseases, researchers at Radboud university medical center now show that COVID-19 is not characterized by a cytokine storm.read more
New insight into the effect of hydroxychloroquine undermines its use in corona11 June 2020
Researchers at Radboud university medical center have discovered an as yet unknown effect of hydroxychloroquine. Raphael Duivenvoorden was interviewed in the program Op1 at NPO1 to elaborate on the findings. It seems unlikely that chloroquine has beneficial effect in corona infections.read more
Henri Timmers appointed professor of Endocrine Diseases8 June 2020
Henri Timmers has been appointed professor of Internal Medicine, with a special focus on endocrine diseases, at Radboud University/Radboud university medical center. This appointment became effective on 1 May 2020.read more
Royal honours for seven Radboud professors24 April 2020
On Friday 24 April, seven professors from Radboud University and Radboud university medical center received telephone calls from the mayors of their towns informing them that they had been awarded royal honours for their exceptional scientific and social merits.read more
Study on effect of BCG vaccine on coronavirus infection in the elderly21 April 2020
Radboud university medical center and UMC Utrecht are working on a joint research project to discover whether the tuberculosis (BCG) vaccine reduces the risk of infection with the coronavirus in people aged 60 or older, or the severity of the symptoms in the event of infection.read more